Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03607565
Recruiting Observational

A New Parameter Derived From DSA to Evaluate Cerebral Perfusion

NCT03607565 · tracked via the Priya Life Science China tracker
Sponsor
Xi'an No.3 Hospital
Phase
Observational
Started
2018-07-15
Last updated
2023-09-01

Condition(s) studied

Cerebral Ischemia

Study summary

This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Cerebral ischemia 2. patients undergone DSA Exclusion Criteria: 1.cerebral hemorrhage

Primary outcome measure(s)

  • the outcomes between good perfusions and poor perfusions — 3 months to 2 years
    Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).

Trial sites (1)

FacilityCityRegionStatus
Xi'an No.3 Hospital Xi'an Shaanxi Recruiting

More Xi'an No.3 Hospital trials in China

Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke Recruiting
Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an Recruiting
Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation Recruiting
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma Recruiting

Other trials for the same condition

Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke Starting soon
Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03607565 on ClinicalTrials.gov ↗ ← All trials in China